Drug Profile
Exenatide sustained-release - Peptron/Yuhan Corporation
Alternative Names: P302; PT 330; PT-302; PT-320; PT-340; SR exenatide - Peptron; YH-14617Latest Information Update: 22 Jul 2022
Price :
$50
*
At a glance
- Originator Peptron
- Developer Peptron; Yuhan
- Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Parkinson's disease
- Preclinical Dyskinesias
- No development reported Alzheimer's disease
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 22 Jul 2022 Phase-II development in Parkinson's disease is ongoing in South Korea (SC) (NCT04269642)
- 28 Mar 2020 No recent reports of development identified for preclinical development in Alzheimer's-disease in South Korea (SC, Controlled release)
- 04 Mar 2020 Preclinical trials in Dyskinesias in South Korea, before March 2020 (SC) (Peptron pipeline, March 2020)